CTI BioPharma to Present at the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 1:30 p.m. ET. The presentation will be available via a live webcast on their website.

CTI BioPharma is focused on developing therapies for blood-related cancers, with its FDA-approved product VONJO^TM designed for myelofibrosis patients. The company is also conducting the Phase 3 PACIFICA study to further assess VONJO's efficacy.

SEATTLE, April 6, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference at 1:30 p.m. ET. The conference will be held in a virtual meeting format.

Presentation details:

Event: 21st Annual Needham Virtual Healthcare Conference
Date: Wednesday, April 13, 2022
Time: 1:30 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO™ is a trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-301518407.html

SOURCE CTI BioPharma Corp.

FAQ

When will CTI BioPharma participate in the Needham Virtual Healthcare Conference?

CTI BioPharma will participate in the Needham Virtual Healthcare Conference on April 13, 2022, at 1:30 p.m. ET.

What is the focus of CTI BioPharma's presentation at the conference?

The presentation will highlight CTI BioPharma's developments in novel targeted therapies for blood-related cancers, including their product VONJO.

How can I watch CTI BioPharma's presentation at the Needham Conference?

You can watch the presentation live on CTI BioPharma's website under the Investors section.

What is VONJO and what is its purpose?

VONJO is an FDA-approved drug by CTI BioPharma for treating adults with myelofibrosis and severe thrombocytopenia.

What study is CTI BioPharma conducting related to VONJO?

CTI BioPharma is conducting the Phase 3 PACIFICA study of VONJO to fulfill post-marketing requirements.